Xenon Pharmaceuticals Inc.

Cynthia Louise Harden

Gregory N Beatch

In certain embodiments, the present disclosure is directed to methods for treating depressive disorders in a human, wherein the methods comprise orally administering a therapeutically effective amount of N-[4-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide (Compound A), to the human in need thereof. The present disclosure is further directed to various improved methods of therapy and administration of Compound A.

Growing community of inventors

Burnaby, Canada

Cynthia Louise Harden